IGF1 and prostate carcinoma: Lin et al.’s Mendelian randomization study was the first to use genetic instrumental variables to directly infer the causality between elevated IGF-I and increased risk of prostate cancer, overcoming confounding and reverse causation in conventional observational studies, but also failed to confirm a linear trend of dose increment (1).